Why Analysts Say CRVS Could Triple: Time to Load Up?

Introduction Corvus Pharmaceuticals (NASDAQ: CRVS) might just be one of the most overlooked opportunities in the biotech sector. With its groundbreaking immunotherapy treatments and expanding clinical trials, CRVS is quietly positioning itself as a potential...